Article Information
History
- January 30, 2023.
Article Versions
- Version 1 (September 13, 2021 - 11:03).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Jeroen Creemers1,2,
- Ankur Ankan3,
- Kit C.B. Roes4,
- Gijs Schröder3,
- Niven Mehra5,
- Carl G. Figdor1,2,
- I. Jolanda M. de Vries1 and
- Johannes Textor1,3,#
- 1Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
- 2Oncode Institute, Nijmegen, The Netherlands
- 3Data Science group, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands
- 4Department of Health Evidence, Section Biostatistics, Radboudumc, Nijmegen, The Netherlands
- 5Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands
- ↵#Corresponding author email address: johannes.textor{at}ru.nl
Posted January 30, 2023.
In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome
